Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Beyond potent cereblon degradation, preclinical data indicate that mezigdomide stimulates T-cell activation and diminishes exhaustion. Reversing T-cell exhaustion offers a vital biological rationale for combining CELMoDs with bispecific antibodies or using them as bridging regimens.

Related Insights

Unlike therapies that can deplete the immune system, mezigdomide enhances T-cell number and function. This unique immune-enhancing property makes it a promising agent to use before, or in combination with, immunotherapies like CAR-T to overcome resistance and improve outcomes in highly refractory patients.

CELMoDs are being actively trialed as a maintenance therapy after CAR T-cell treatment. The strategy is to leverage the CELMoDs' ability to enhance T-cell function and upregulate effector T-cells to boost the activity and persistence of the CAR-T product, potentially leading to more durable responses and preventing relapse.

Unlike IMiDs (lenalidomide) which only close the Cereblon E3 ligase complex by 15-20%, mezigdemide achieves 100% closure. This leads to more robust degradation of key proteins, causing powerful direct myeloma cell destruction and enhanced immune activation, earning it the nickname 'CAR T in a pill.'

New cereblon modulating agents (CELMoDs) like mezigdemide are showing significant efficacy in patients refractory to lenalidomide and anti-CD38 antibodies. The Successor-2 trial demonstrated a dramatic progression-free survival benefit, highlighting a new therapeutic avenue for a difficult-to-treat patient population by overcoming prior treatment resistance.

Unlike older IMiDs where T-cell effects are secondary, CELMoDs have a powerful, independent pro-T-cell mechanism. This dual action is so significant that in the future, CELMoDs will be prescribed not just for their direct anti-myeloma effects, but specifically to enhance the efficacy of T-cell therapies like CAR-T and bispecific antibodies.

Next-generation CELMoDs (iberdomide, mezagdomide) show promise beyond direct tumor killing. Their ability to reduce or reverse T-cell exhaustion suggests they could be used to 'prime' a patient's immune system, potentially restoring function before or after treatment with a CAR-T or bispecific T-cell engager.

In a heavily pretreated population, mezigdemide plus dexamethasone achieved a 50% response rate in patients refractory to prior BCMA-based approaches, including antibody-drug conjugates, bispecifics, and CAR T-cell therapy. This demonstrates a distinct mechanism that can overcome resistance to the latest immunotherapies.

Unlike IMiDs, which only partially engage the target, CELMoDs like iberdomide are larger molecules that fully close the cereblon E3 ligase pocket. This maximizes degradation of target proteins Ikaros and Aiolos, leading to greater potency and what is described as "hitting the death star" of the myeloma cell.

New oral CELMoDs like mezigdemide show a surprising ability to make previously ineffective drugs, like bortezomib and carfilzomib, work again. This resensitization mechanism offers a powerful strategy to recycle older therapies, expanding options for heavily pretreated patients.

Beyond their direct anti-myeloma effects, CELMoDs potently activate the immune system. This positions them as ideal partners for immunotherapies like CAR T and bispecifics, with the potential to restore immune function and overcome resistance to T-cell redirecting therapies.